The majority of patients with congenitally corrected transposition the great arteries, also known as arteries {S,L,L} have ventricular septal defects (VSD), most commonly perimembranous VSD (pmVSD). Transcatheter device closure pmVSD in these has not been widely described. We present a case L-TGA an Amplatzer Duct Occluder II (ADOII) using deployment starting subpulmonary left ventricle. demons...

OBJECTIVES The aim of this study is to evaluate our clinical experience using an Amplatzer septal occluder for catheter closure of a secundum atrial septal defect under transthoracic echocardiography guidance without general anaesthesia. METHODS Patients eligible for transcatheter atrial septal defect closure were selected using transthoracic echocardiography. The largest defect diameter meas...

OBJECTIVES The aim of this study was to close muscular ventricular septal defects (MVSDs) in children, with a new device, the Amplatzer ventricular septal defect occluder (AVSDO). BACKGROUND The design of previously used devices for transcatheter closure of MVSDs is not ideal for this purpose and their use has been limited by several drawbacks. METHODS Six patients, aged 3 to 10 years, with...

Today, congenital heart diseases may be treated without surgery through advances in interventional cardiology. However, complications such as infection and thrombus formation may develop due to foreign materials used during these procedures. Surgical intervention may be required for the removal of the device utilized for the procedure. In this case report, we present the surgical treatment of a...

BACKGROUND Percutaneous occlusion of secundum type atrial septal defect with an Amplatzer device is an effective treatment alternative. However, there is little information about the use of this treatment for large defects. PATIENTS AND METHOD We retrospectively analyzed the initial and follow-up findings in 31 patients aged 41 18 years who had large atrial septal defects (>= 30 mm diameter)....

Ma Percutaneous left atrial appendage closure technology for stroke prevention in patients with atrial fibrillation has significantly advanced in the past 2 decades. Several devices are under clinical investigation, and a few have already received Conformité Européene (CE)-mark approval and are available in many countries. The WATCHMAN device (Boston Scientific, Natick, Massachusetts) has the m...

T he first atrial septal defects (ASDs) were closed percutaneously in 1974 and reports about their closure published in 1976. In the 1980s the Rashkind occluder was introduced and revived the interest in the topic, focusing for the first time on the patent foramen ovale (PFO). This device is still available in two modified versions. Its initial name, Rashkind Clamshell occluder, has been change...

BACKGROUND Atrial fibrillation (AF) is a cardiac arrhythmia with high risk for thromboembolic events, specially stroke. OBJECTIVE To assess the safety of left atrial appendage closure (LAAC) with the Amplatzer Cardiac Plug for the prevention of thromboembolic events in patients with nonvalvular AF. METHODS This study included 15 patients with nonvalvular AF referred for LAAC, 6 older than 7...

BACKGROUND Transcatheter closure of ostium secundum atrial septum defect (ASDII) using the new self-centering occluder, Amplatzer Septal Occluder (ASO), has been well developed in recent years. We describe the importance and role of transesophageal echocardiography (TEE) in the selection and closure of such defects. METHODS Thirty patients referred for transcatheter closure of ASDII by ASO we...

BACKGROUND Arterioportal fistula (APF) is an abnormal, direct connection between hepatic artery or its branch and the portal vein. Fistula can be acquired or, rarely, congenital. One of the acquired causes of fistula is a liver biopsy. Patients with liver cirrhosis are particularly vulnerable to its development due to the large number of performed biopsies. APF increases mortality and morbidity...